Executive Summary
Medicare TAVI durability has a new shape: the hazard of reintervention quadruples after 7 years, with valve-in-valve now accounting for 97% of late reoperations, according to a Bayesian analysis of 324,701 TAVI patients in the Annals of Thoracic Surgery. The accompanying JTCVS commentary by Pereira flags the alarming one-year mortality in younger, lower-risk Medicare patients undergoing reintervention — exactly the cohort the ESC 2025 just nudged toward TAVI at age 70. Layered on top, a separate 11,000-patient European registry in American Heart Journal shows 4% of "uncomplicated" TAVI patients die within a year — overwhelmingly non-cardiovascular — which tightens the case for harder patient selection and complicates any move toward routine TAVI in lower-risk, longer-lived patients.
- Late TAVI reintervention now runs at 0.98% annual hazard after year 7 vs 0.26% in the first 3.5 years, with valve stenosis driving 70.8% of late cases (Annals of Thoracic Surgery).
- Iliofemoral access-site calcium volume independently predicts 5-year mortality after TAVI (HR 1.24) without affecting 30-day complications — a systemic disease marker, not a procedural one (Clinical Research in Cardiology, N=1,067).
- RV dyssynchrony by speckle-tracking (RVSD4 >18 ms) carries a 4-fold adjusted hazard of 3-year mortality post-TAVI in 1,052 patients (QIMS).
- Iatrogenic posterior leaflet perforation during TriClip XTW deployment produced unsalvageable severe residual TR — a reminder that tricuspid TEER complications are not always plug-closable (JACC Case Reports).
- A Montana rural TAVI program is paused after surgeon and cardiologist complaints about patient selection, including a TAVI performed for aortic regurgitation without severe stenosis (Cardiovascular Business / Montana Free Press).
What to watch: The next ACC/AHA valve guideline update will have to reckon with these Medicare reintervention curves before endorsing any ESC-style lowering of the TAVI age threshold below 70.
Aortic Valve (TAVR/TAVI)
The durability conversation just got harder to wave away. The Mount Sinai/Medicare analysis of 324,701 TAVI patients (Alabbadi et al., Annals of Thoracic Surgery) identifies three reintervention eras: early (<3.5y, 0.26% annual hazard), mid-term (3.5–7y, 0.35%), and late (≥7y, 0.98%). Valve stenosis drives 70.8% of late reinterventions, and 97.2% are now valve-in-valve — a TAV-in-TAV future the field has not stress-tested at scale. The accompanying JTCVS commentary by Pereira calls the one-year mortality after reintervention in younger Medicare patients "alarming." [NOTABLE] This matters because the ESC 2025 just lowered the TAVI-preferred threshold to age 70 — a cohort with a realistic chance of needing that late reintervention. ACC/AHA 2020 still favors SAVR under 65 on durability grounds, and these data argue against shrinking that floor.
Three companion papers tighten patient selection. The D'Ascenzo registry in American Heart Journal (N=11,000+, 18 European sites, retrospective) shows 4% of uncomplicated TAVIs die within a year, 3.3% from non-cardiovascular causes — AF, COPD, severe CKD, and reduced LVEF predicting death. Iliofemoral calcium volume predicts long-term mortality independently of procedural risk, and RV dyssynchrony (RVSD4) carries HR 4.0 for 3-year death. CT-derived LAVI ≥53 mL/m² confers HR 4.2 for MACE. None of this is in current TAVI risk scores. The signal: peri-procedural safety has plateaued; the next mortality gains come from saying no.
Mitral Valve
No high-tier mitral trial data today. A Journal of Visualized Surgery commentary on complex mitral annular calcification argues surgical access still matters — a counterweight to the rising enthusiasm for TMVI in MAC, which the ESC 2025 rates only Class IIb at experienced centres. For atrial functional MR, the reference literature continues to support TEER over medical therapy alone (HR 0.65 for death/HF hospitalization in the OCEAN-Mitral/REVEAL-AFMR analysis), aligning with the ESC 2025 formal recognition of atrial SMR as a distinct entity. ACC/AHA 2020 has no formal atrial SMR pathway, and no US guideline has yet matched the ESC's Class I designation for TEER in ventricular SMR. Practice in the US is running ahead of the ACC/AHA text on this point; the next update will need to catch up to COAPT's 5-year data and RESHAPE-HF2.
Tricuspid Valve
A sobering procedural reminder: a JACC Case Reports description of iatrogenic posterior leaflet perforation during TriClip XTW deployment ended with severe residual TR and a failed plug attempt. Single case, but worth flagging now that the ESC 2025 has elevated transcatheter tricuspid intervention to Class IIa, LOE A. The surgical comparator the ESC 2025 also strengthened: TV surgery for symptomatic severe primary TR is now Class I (was IIa in ACC/AHA 2020). The risk in the field's enthusiasm — fueled by TRILUMINATE Pivotal, Tri.Fr, and TRISCEND II — is forgetting that TR TEER benefit in those trials was driven by symptoms and QoL, not mortality, and that complications can be unsalvageable when leaflet tissue fails. Real-world TTVR data from the STS/ACC TVT Registry show 98.4% procedural success and 3.1% 30-day mortality with EVOQUE, but a 15.9% new pacemaker rate. The technology works. Patient selection still decides everything.
Surgical vs. Transcatheter Comparisons
Today's Medicare reintervention data is itself the comparison: a SAVR redo is a well-characterized operation with predictable risk; TAV-in-TAV at 7+ years is an emerging procedure with limited durability data and rising volume. The Pereira JTCVS commentary makes the surgical case explicitly: the younger Medicare TAVI cohort that needs reintervention is dying at unacceptable rates within a year. The reference literature — including the recent JACC meta-analysis showing TAVR mortality advantage at 5 years in lower-risk patients — is being read against an emerging counter-narrative that excludes intermediate-risk trials and finds the difference vanishes. The ESC 2025 moved to TAVI-preferred at age 70; ACC/AHA 2020 holds the line at 80. Today's data favors the ACC/AHA's caution.
Device & Technology
Two procedural innovations worth noting. A modified "UNICORN" guide-anchoring technique for valve-in-valve TAVI in a failed Perceval sutureless bioprosthesis (JACC Case Reports) enabled leaflet laceration when both chimney stenting and BASILICA were precluded — an increasingly relevant problem as sutureless surgical valves age into ViV territory. A single-admission hybrid robotic CABG + transcarotid TAVI demonstrates that alternative access remains a live problem in patients with hostile iliofemoral anatomy and severe PAD. And GPT-based extraction of TAVI variables from free-text records hit accuracy of 0.657–1.00 across 108 cases — feasible for observational research, premature for regulatory submissions.
Regulatory & Policy
A Montana Free Press investigation into the paused TAVI program at Benefis Health System reports a TAVI performed for aortic regurgitation without severe stenosis, with subsequent failure attributed to insufficient calcium for anchoring. Two physicians — a cardiac surgeon and a cardiologist — went on the record describing concerns about patient selection being met with institutional pushback. The case is a policy story, not just a clinical one: as TAVI volumes scale into lower-volume, rural centers, the question of program oversight and minimum case-volume thresholds reopens. The MedPage Today follow-up indicates the program remains under fire. No FDA or CMS action announced today.
Industry & Market
Edwards drew a 111,843-share addition from Parnassus Investments — a small institutional vote of confidence as the TAVI durability conversation intensifies. The clinical signal cuts both ways for Edwards: if late reinterventions concentrate in TAV-in-TAV procedures, that's incremental device volume. If guidelines tighten on the back of today's Medicare data, the upside in low-risk patients narrows.
Financial Analysis
Today's clinical data has direct commercial implications. The Medicare reintervention curve suggests Edwards and Medtronic face a long-tail ViV opportunity but also a guideline-risk overhang. The D'Ascenzo 4% one-year mortality finding argues for tighter patient selection — a near-term volume headwind, a long-term durability tailwind for the TAVI thesis. Boston Scientific's TR franchise (TriClip) gets a procedural-risk reminder from today's leaflet perforation case but retains the strongest guideline tailwind in the space. Abbott's MitraClip continues to benefit from ESC 2025's Class I upgrade for ventricular SMR, though shares have not reflected this clinical lead.
Valve Industry Stocks
Edwards Lifesciences (EW)
- Close: $85.76, down $0.22 (-0.26%) on the day; 6-month +3.23%
- Market cap $49.4B; trailing P/E 46.4, forward 25.5; beta 0.87; 52-week range $72.30–$89.48
- Analyst target $96.92 (range $84–$110, 26 analysts); consensus buy
- Next earnings 2026-07-23 (EPS est $0.74; revenue est $1.70B)
- Commentary: Holding near 52-week highs. Today's Medicare durability data is a longer-term variable; near-term TAVI volume and TriClip/PASCAL competitive dynamics dominate the print.
Medtronic (MDT)
- Close: $80.33, up $0.08 (+0.10%); 6-month -18.31%
- Market cap $103.1B; trailing P/E 21.5, forward 12.5; beta 0.60
- Analyst target $98.58 (range $78–$121, 26 analysts); consensus buy
- Next earnings 2026-08-18 (EPS est $1.39; revenue est $9.55B)
- Commentary: The 6-month drawdown reflects broader portfolio drag. Evolut remains the durability story to watch as Medicare reintervention data matures.
Abbott (ABT)
- Close: $89.65, up $0.48 (+0.54%); 6-month -27.73%
- Market cap $156.2B; trailing P/E 25.1, forward 14.8; beta 0.62
- Analyst target $117.29 (range $92–$135, 24 analysts); consensus buy
- Next earnings 2026-07-16 (EPS est $1.28; revenue est $12.53B)
- Commentary: Structural heart (MitraClip, Navitor, TriClip) remains a growth pillar but is masked by broader diagnostics weakness. ESC 2025 Class I for TEER in ventricular SMR is an underappreciated tailwind.
Boston Scientific (BSX)
- Close: $47.17, down $1.17 (-2.42%); 6-month -49.05%
- Market cap $70.1B; trailing P/E 19.7, forward 12.7; beta 0.56
- Analyst target $78.17 (range $55–$106, 30 analysts); consensus strong buy
- Next earnings 2026-07-29 (EPS est $0.83; revenue est $5.38B)
- Commentary: Steep 6-month decline at odds with ACURATE neo/Lotus and Sentinel positioning. Today's iliofemoral calcium mortality data could expand Sentinel-style risk-stratification adjuncts.
Anteris Technologies (AVR.AX)
- Close: A$13.12, down A$0.38 (-2.81%); 6-month +74.24%
- Market cap A$1.3B; forward P/E -6.0; beta 0.73; 52-week range A$4.68–$13.85
- Single-analyst target A$13.00
- Commentary: DurAVR continues to attract durability-thesis capital — exactly the angle today's Medicare reintervention data spotlights.
Market outlook: The clinical story today — late TAVI reinterventions are increasing, and most patients dying after "successful" TAVI are dying of non-cardiac causes — argues for a barbell. Companies with the strongest durability narrative (Anteris, Edwards' RESILIA platform) and those with TR/MR growth runways (Abbott, Boston Scientific, Edwards) sit on the right side of the next guideline cycle. Pure aortic incumbents face the harder question.
Clinical Trial Updates
A French cluster RCT (NCT_05237804, 828 patients enrolled) is testing a multi-component intervention to reduce time-to-TAVI — the primary endpoint is the proportion treated within 2 months of indication. Treatment delays are a real outcome variable now that TAVI waitlist mortality is documented. Data analysis pending.
Social & Conference Highlights
The 2025 Accra Declaration from the Pan-African Society for Cardiothoracic Surgery continues to draw attention for its emphasis on cost-effective valve surgery and regional fellowship infrastructure — a useful counterweight to the high-tech TAVI/TEER discourse dominating Western meetings.
The Medicare reintervention curve is the data point the next ACC/AHA guideline writers cannot ignore. Expect durability — not procedural safety — to define the next cycle of the SAVR-vs-TAVI debate, and expect patient selection to start mattering as much as device choice.